Industry News
-
EpiCure Receives $1.5M NIH Grant to Advance AAV Gene Therapy for SLC6A1-Related Disorder
Jul 20 2026 -
AbelZeta Receives EMA PRIME Designation for Dual-Target CAR-T Therapy in Refractory Lupus
Jul 20 2026 -
4DMT Reports Two-Year Data for AAV Gene Therapy 4D-150 in Wet AMD
Jul 19 2026 -
Industry Backs FDA Draft Guidance on NGS Safety Assessment for Genome Editing Therapies, While Seeking Greater Clarity
Jul 17 2026 -
Umoja Receives FDA IND Clearance for CD22-Directed In Vivo CAR-T Therapy
Jul 16 2026 -
Johnson & Johnson Discontinues JNJ-1887 Gene Therapy Program for Geographic Atrophy
Jul 16 2026 -
Nava Therapeutics Launches with $89M to Advance Extrahepatic LNP Delivery for In Vivo CAR-T and Kidney Gene Editing
Jul 16 2026 -
REGENXBIO Announces Proposed $100M Public Offering as Late-Stage AAV Pipeline Advances
Jul 16 2026 -
Voyager Reports Six-Month NHP Toxicology Data for Tau-Targeted AAV Gene Therapy in Alzheimer’s Disease
Jul 15 2026